ARAlison W. Rebman

Alison W. Rebman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alison W. Rebman has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Borrelia burgdorferi disrupts gut barrier functions and microbiota–antibody interactions

    by Shilpa Sachan, Giang Vu Vi Tran, Kimberly J. Olsen, Heather Kulaga, Anne Day, Hannah P. Savage, Alison W. Rebman, John N. Aucott, Isabel A. Jimenez, Cory F. Brayton, et al.

    Lyme disease, an emerging tickborne disease caused by Borrelia burgdorferi (Bb), can result in myriad symptoms of unknown causes in humans. Here, we show that Bb rapidly disrupts the gastrointestinal immune barrier in infected mice, inducing a “leaky gut” syndrome, characterized by increased gut permeability, systemic endotoxemia, elevated LPS binding protein and intestinal fatty acid binding protein, and altered blood leukocyte profiles. Patients with acute Lyme disease showed similar blood changes that correlated with disease symptoms and liver function measurements and largely resolved after antibiotic treatment. Mechanistically, Bb infection triggered mild early inflammation in the small intestine and suppressed humoral immunity to the microbiota, resulting in reduced IgA coating of fecal microbes and decreased antimicrobial serum IgG, despite the increased gut permeability. These defects preceded shifts in later observed gut bacterial composition and short-chain fatty acid production. Together, our findings identify mucosal barrier dysfunction and impaired antimicrobial humoral immunity as potential drivers of Bb-induced disease.

  • Open Access

    Early brain changes in Lyme disease are associated with clinical outcomes

    by Cherie L. Marvel, Alison W. Rebman, Kylie H. Alm, Pegah Touradji, Arnold Bakker, Prianca A. Nadkarni, Deeya Bhattacharya, Owen P. Morgan, Amy Mistri, Christopher C. Sandino, et al.

    Lyme disease (LD) is a tick-borne infection due to the bacteria Borrelia burgdorferi. After antibiotic treatment, 10-20% of patients develop post-treatment Lyme disease (PTLD). Neurological symptoms are commonly reported in PTLD. This case-control study tested the hypothesis that brain changes occur in LD and are related to clinical outcomes. A working memory task was administered during functional MRI (fMRI), in conjunction with cognitive assessments and health surveys, to examine brain function and clinical outcomes in people with acute LD disease (n=20; 55.0% male; mean age (range) = 52.3 (26-78)). Assessments were conducted a mean of 15.2 days (range: 1-51) after initial antibiotic treatment [i.e., “baseline”] and again 6 months later. A well-matched group of healthy controls (HC, n=19; 31.6% male; mean age (range) = 46.5 (19-60)) was also assessed 6 months apart. At the 6-month follow-up, the LD group was categorized into those who returned to health (RTH, n=11) and those reporting persistent symptoms (sPTLD, n=9) to determine if early brain changes predicted subsequent outcomes. FMRI data from both LD groups were compared to the HC group. Regions of interest (ROI) values were obtained from the fMRI results and correlated to cognitive performance and symptom survey scores. At baseline, brain activity in the RTH group was significantly increased relative to that of HC. Notably, 64% of the RTH group’s activation clusters were in white matter, confirmed by segmentation analysis. ROIs created from the RTH vs. HC fMRI results, including white matter regions, significantly correlated with better self-reported clinical outcomes. At the 6-month follow-up, most of the RTH group’s activity had normalized relative to HC, and associations between ROI values and clinical outcomes were no longer observed. The sPTLD group showed few fMRI activation differences versus the HC group at either time point, and no significant associations were observed between ROI values and clinical outcomes. Instead, the sPTLD group’s ROI values negatively correlated with cognitive performance at the 6-month follow-up. These results indicate that early brain changes in LD predict future RTH status. Increased brain activation during cognition, including in white matter, may reflect a healing response without which LD patients are more likely to develop PTLD. The observed increased activation in white matter suggests specific mechanisms, such as appropriate astrocyte reactivity, and require further investigation. Understanding how increased brain activity relates to RTH in LD will aid early identification of those vulnerable to developing PTLD and guide treatment.

  • Open Access

    Contrast Sensitivity Loss in Patients With Posttreatment Lyme Disease

    by Alison W. Rebman, Ting Yang, John N. Aucott, Erica A. Mihm, Sheila K. West

    Purpose: Posttreatment Lyme disease (PTLD) is marked by neurologic symptoms, cognitive impairment, and significant symptom burden, including fatigue and ocular complaints. The purpose of this study was to determine whether contrast sensitivity (CS) is altered in patients with PTLD compared with healthy controls and, second, whether CS is associated with cognitive and/or neurologic deficits. Methods: CS was measured using a Pelli–Robson chart with forced-choice procedures, and the total number of letters read was recorded for each eye. CS impairment was defined for age Results: CS impairment was associated with an increased odds of being in the PTLD group that was 2.6 times as high as those without CS impairment (odds ratio, 2.6; 95% confidence interval, 1.3–5.2). Neither cases nor controls had significant distance acuity impairment. CS impairment was not associated with any of the ocular complaints in cases but was borderline associated with neurologic abnormalities and cognitive impairment. Conclusions: CS impairment in patients with PTLD is linked to signs of cognitive and neurologic impairment and may be a marker of illness severity. Translational Relevance: Further investigation into the value of testing CS impairment in PTLD cases is warranted, especially if it is an indicator of cognitive or neurologic manifestations.